How far along are we in revealing the connection between metformin and colorectal cancer? (CROSBI ID 298680)
Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija
Podaci o odgovornosti
Cigrovski Berković, Maja ; Mikulić, Danko ; Bilić- Ćurčić, Ines ; Mrzljak, Anna
engleski
How far along are we in revealing the connection between metformin and colorectal cancer?
Colorectal cancer (CRC) is among the most prevalent cancers worldwide, and its prevention and reduction of incidence is imperative. The presence of diabetes has been associated with a 30% increased risk of CRC, likely through the mechanism of hyperinsulinemia, which promotes tumorigenesis via the insulin receptor in the epithelium or by insulin-like growth factor pathways, inflammation, or adipokines, inducing cancer cell proliferation and cancer spread. Metformin, the first-line agent in treating type 2 diabetes, has a chemopreventive role in CRC development. Additionally, preclinical studies suggest synergistic effects of metformin with oxaliplatin in inhibiting in vitro models of colon cancer. Although preclinical studies on the post diagnostic use of metformin were promising and suggested its synergistic effects with chemotherapy, the data on the possible effects of metformin after surgery and other CRC treatment in the clinical setting are less conclusive, and randomized controlled trials are still lacking.
metformin ; type 2 diabetes mellitus ; colorectal cancer ; chemoprevention ; recurrence-free survival ; surgery
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
27 (14)
2021.
1362-1368
objavljeno
1007-9327
2219-2840
10.3748/wjg.v27.i14.1362
Povezanost rada
Kliničke medicinske znanosti, Temeljne medicinske znanosti